產(chǎn)品屬性：
產(chǎn)品名稱 | 規(guī)格 | CAS號 | 型號 |
Euphol | 1mg 5mg 10mg | 514-47-6 | EY-Y0164585 |
Cas No.514-47-6
別名 N/A
化學(xué)名 N/A
分子式 C30H50O
分子量 426.72
溶解度 Soluble in DMSO
儲存條件 Store at-20°C, protect from light
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述：
Euphol is a tetracyclic triterpene alcohol isolated from the sap of Euphorbia tirucalli with anti-mutagenic, anti-inflammatory and immunomodulatory effects, orally active. Euphol inhibits the monoacylglycerol lipase (MGL) activity via a reversible mechanism (IC50=315 nM). MGL inhibition in the periphery modulates the endocannabinoid system to block the development of inflammatory pain[1].
Euphol (0.01-0.3 mM; 24-72 hours) markedly inhibits T47D cells proliferation, the IC50 values of euphol treatment for 24, 48 and 72 h were 0.26, 0.22 and 0.13 mM, respectively[2].Euphol (0.03 mM; 48 or 72 hours) leads to cell cycle arrest by regulating expression of cell cycle-associated proteins[2]. Cell Proliferation Assay[2] Cell Line: T47D cells
[1]. Dutra RC, et al. Euphol, a tetracyclic triterpene produces antinociceptive effects in inflammatory and neuropathic pain: the involvement of cannabinoid system. Neuropharmacology. 2012 Sep;63(4):593-605. [2]. Wang L, et al. Euphol arrests breast cancer cells at the G1 phase through the modulation of cyclin D1, p21 and p27 expression. Mol Med Rep. 2013 Oct;8(4):1279-85.
關(guān)鍵字： 514-47-6;C30H50O;Euphol;
上海一研生物科技有限公司Shanghai yiyan bio-technology Co. Ltd.主要從事免疫學(xué)、分子生物學(xué)和常規(guī)生化試劑等為一體的科研產(chǎn)品銷售企業(yè)，公司自成立以來，秉承""全心全意服務(wù)于科研工作者""的企業(yè)理念，立足生物科技領(lǐng)域，運用生物技術(shù)和科研試劑，發(fā)展現(xiàn)代生物科技，為各類大中小醫(yī)院及其它醫(yī)療機構(gòu)、高等院校、科研院所、企事業(yè)單位提供優(yōu)質(zhì)的產(chǎn)品，服務(wù)生物科技領(lǐng)域的科學(xué)研究人員。
公司具有對普通貨物、冷藏及冷凍倉庫的存儲、包裝及運輸能力。
公司將始終堅持信譽立業(yè)、以人為本、質(zhì)量保證、誠信服務(wù)的宗旨，不斷拼搏，開拓進取，與各界朋友攜手共創(chuàng)美好未來。